vimarsana.com

Latest Breaking News On - Precision interventions - Page 1 : vimarsana.com

When the Third Time Is Not the Charm—Trial Outcomes in Idiopathic Pulmonary Fibrosis | Pulmonary Medicine | JAMA

Docs Debate Home Spirometry

Biologic agent dupilumab effective in improving asthma exacerbations and lung function, study shows

A new medication has been added to the treatment options for children with moderate-to-severe asthma. In a late-stage clinical trial, the biologic agent dupilumab reduced the rate of severe asthma attacks and improved lung function and asthma control for children ages 6 to 11.

New study focuses on personalized therapies for people with severe asthma

New study focuses on personalized therapies for people with severe asthma A new phase 2 clinical trial of multiple therapies for severe asthma is underway in Northeast Ohio, with a focus on personalized therapies based on genetics, family history, lifestyle and environmental factors. The Precision Interventions for Severe and/or Exacerbation-Prone Asthma Network (PrecISE) study, sponsored by the National Heart, Lung and Blood Institute (NHBLI), is enrolling patients at Cleveland Clinic and University Hospitals Rainbow Babies & Children s Hospital. The multicenter study involves 30 clinical sites in the United States, Canada and the United Kingdom that will collectively enroll 650 adult and 150 adolescent volunteers, age 12 and over. Prospective participants will be patients with poorly controlled asthma or frequent asthma attacks.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.